Development of a novel Ara h 2 hypoallergen with no IgE binding or anaphylactogenic activity

BACKGROUND: To date, no safe allergen-specific immunotherapy for patients with peanut allergy is available. Previous trials were associated with severe side effects. OBJECTIVE: We sought to determine the relative importance of conformational and linear IgE-binding epitopes of the major peanut allerg...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Allergy Clin Immunol
Autors principals: Tscheppe, Angelika, Palmberger, Dieter, van Rijt, Leonie, Kalic, Tanja, Mayr, Vanessa, Palladino, Chiara, Kitzmüller, Claudia, Hemmer, Wolfgang, Hafner, Christine, Bublin, Merima, van Ree, Ronald, Grabherr, Reingard, Radauer, Christian, Breiteneder, Heimo
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7100897/
https://ncbi.nlm.nih.gov/pubmed/31525384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaci.2019.08.036
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars